Arcus Biosciences (RCUS) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03969F1093
Arcus Biosciences, Inc. is a US-based clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative cancer therapies.
The company's diverse pipeline includes advanced products such as Domvanalimab, an anti-TIGIT monoclonal antibody, and AB308, another anti-TIGIT monoclonal antibody, both undergoing clinical trials for various cancer types.
Additionally, Arcus Biosciences is working on Etrumadenant, a promising dual adenosine receptor antagonist, and Quemliclustat, a CD73 inhibitor, alongside Zimberelimab and AB521 among others, all at different stages of clinical development.
With preclinical pipeline products like AB598 and AB801, the company is also exploring innovative solutions for cancer treatment beyond its current offerings.
Arcus Biosciences is actively engaged in collaborations with leading entities such as AstraZeneca and BVF Partners L.P., demonstrating its commitment to advancing groundbreaking therapies for cancer and inflammatory diseases.
Established in 2015, Arcus Biosciences is headquartered in Hayward, California. To learn more about their endeavors, visit their website at https://www.arcusbio.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
RCUS Stock Overview
| Market Cap in USD | 1,326m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2018-03-15 |
RCUS Stock Ratings
| Growth 5y | 0.63 |
| Fundamental | -62.2 |
| Dividend | - |
| Rel. Performance vs Sector | -2.81 |
| Analysts | 4.45/5 |
| Fair Price Momentum | 13.27 USD |
| Fair Price DCF | - |
RCUS Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
RCUS Growth Ratios
| Growth 12m | -18.87% |
| Growth Correlation 12m | -37% |
| Growth Correlation 3m | -41% |
| CAGR 5y | 8.63% |
| Sharpe Ratio 12m | -0.36 |
| Alpha vs SP500 12m | -56.87 |
| Beta vs SP500 5y weekly | 1.50 |
| ValueRay RSI | 41.31 |
| Volatility GJR Garch 1y | 68.77% |
| Price / SMA 50 | -10.29% |
| Price / SMA 200 | -11.84% |
| Current Volume | 505.3k |
| Average Volume 20d | 521.6k |
External Links for RCUS Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 09, 2024, the stock is trading at USD 15.26 with a total of 505,292 shares traded.
Over the past week, the price has changed by -1.55%, over one month by -10.08%, over three months by +0.33% and over the past year by -23.12%.
According to ValueRays Forecast Model, RCUS Arcus Biosciences will be worth about 15 in May 2025. The stock is currently trading at 15.26. This means that the stock has a potential downside of -1.51%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 39.2 | 157 |
| Analysts Target Price | 43.1 | 182 |
| ValueRay Target Price | 15 | -1.51 |